Supplementary Figure 25. Subgroup analysis of Mortality of Low Risk Studies for COVID-19 according to Severity of ARDS

Study	Doses of glucocorticoids (Equivalent methyl(prednisolone)	Types of glucocorticoids	Glucocorticoids (No. events/total)	Control (No. events/total)	RR	95% CI	Weight %	Favours glucocorticoids Favours control	Time frame of mortality	Incidence of events in control	Severity of illness	Primary data type	Risk of bias
With mild ARDS													
Fernandez–Cruz&Ruiz–Antoran, 2020	NA	Methylprednisolone	7/96	7/43	0.44	[0.16; 1.20]	25.1		30–day (30 days follow–up)	0.16	Severe	Adjusted OR	Low
Subtotal (random effect)					0.44	[0.16; 1.20]	25.1						
Heterogeneity: I^2 = NA%, p = NA													
With severe ARDS													
Fernandez–Cruz&Ruiz–Antoran, 2020	NA	Methylprednisolone	38/144	9/15	0.43	[0.22; 0.82]	58.7		30–day (30 days follow–up)	0.6	Critically severe	Adjusted OR	Low
Bartoletti&Marconi, 2020	Median of 80 or 107 mg/day	Multiple types	23/52	45/83	0.27	[0.08; 0.92]	16.2		30–day (30 days follow–up)	0.54	Critically severe	Adjusted OR	Low
Subtotal (random effect)					0.39	[0.22; 0.69]	74.9						
Heterogeneity: I^2 = 0%, p = .31													
Total (random effect)					0.40	[0.24; 0.66]	100.0						
Prediction interval						[0.02; 10.16]							
Heterogeneity: I^2 = 0%, p = .76													
Test for overall (random effect): z = −3.60 (p < .001)													
Test for between–subgroup–differences (random effect): χ^2_1 = 0.06, df = 1 (p = .81)								Risk Ratio (95% CI)					